ENROLLED ORIGINAL
AN ACT
_______________
IN THE COUNCIL OF THE DISTRICT OF COLUMBIA
_________________________
To amend, on an emergency basis, due to congressional review, the Legalization of Marijuana
for Medical Treatment Initiative of 1999 to allow the Alcoholic Beverage and Cannabis
Board (“ABC Board”) to issue temporary non-resident registration identification cards
that are valid for periods between 3 days and no longer than one year in length, allow
licensed testing laboratories to receive and test samples of medical cannabis products
from qualifying patients, allow licensed testing laboratories to conduct quality assurance
or research and development testing for cultivation centers and manufacturers, amend the
definition of a social equity applicant to include arrests and convictions of qualifying
family members for a cannabis or drug offense, expand the list of eligible family
members under the social equity applicant definition to include siblings and grandparents,
clarify that existing licensed cultivation centers and retailers and applicants that scored
150 points or more during the open application period that occurred between November
29, 2021 and March 28, 2022, that are authorized by statute to receive a cultivation
center, manufacturer, or retailer license apart from a designated open application period
are not counted in calculating the 50% set aside requirement, clarify that the 5 cultivation
center registration applicants that scored 150 points or more during the same open
application period shall automatically receive a manufacturer license provided that they
pay the annual fee and register with the ABC Board, allow the Alcoholic Beverage and
Cannabis Administration to issue conditional licenses to testing laboratory applicants,
and to waive the application fee for testing laboratory licenses.
BE IT ENACTED BY THE COUNCIL OF THE DISTRICT OF COLUMBIA, That this
act may be cited as the “Medical Cannabis Clarification and Non-Resident Patient Access
Congressional Review Emergency Amendment Act of 2024”.
Sec. 2. The Legalization of Marijuana for Medical Treatment Initiative of 1999, effective
February 25, 2010 (D.C. Law 13-315; D.C. Official Code § 7-1671.01 et seq.), is amended as
follows:
(a) Section 2 (D.C. Official Code § 7-1671.01) is amended as follows:
(1) Paragraph (13B)(B) is amended by striking the phrase “30-day registration
1
 ENROLLED ORIGINAL
identification card” and inserting the phrase "registration identification card valid for periods
established by the ABC Board by rulemaking, which are between 3 days and no longer than one
year in length” in its place.
(2) Paragraph (20C)(B) is amended by striking the phrase “or has a non-
parent legal guardian who is or has been incarcerated” and inserting the phrase “or has a non-
parent legal guardian, or a grandparent or a sibling who is or has been arrested, convicted, or
incarcerated”.
(b) Section 6(b) (D.C. Official Code § 7-1671.05(b)) is amended as follows:
(1) Paragraph (4) is amended as follows:
(A) Subparagraph (A) is amended by striking the phrase “30 days”
and inserting the phrase "periods established by the ABC Board by rulemaking, which are
between 3 days and no longer than one year in length”.
(B) Subparagraph (B) is amended by striking the phrase "30-day”.
(2) Paragraph (5)(C) is amended by striking the phrase "3 years.” and
inserting the phrase “3 years, except for temporary non-resident registration identification cards
that are valid for periods established by the ABC Board by rulemaking, which shall be between 3
days and no longer than one year in length.” in its place.
(3) A new paragraph (11A) is added to read as follows:
“(11A) Allow testing laboratories to:
“(A) Receive and test samples of medical cannabis products from
qualifying patients; provided, that the qualifying patient must present proof that he or she is
currently registered, and that the medical cannabis product was purchased from a retailer or
internet retailer licensed with ABCA.
“(B) Receive and test samples of medical cannabis products from licensed
cultivation centers or manufacturers for purposes of quality assurance or research and
development. Samples collected for quality assurance or research and development testing may
be selected by the cultivation center or manufacturer non-randomly. Any tests conducted for
purposes of quality assurance or research and development shall not satisfy the requirements of
paragraphs (8) through (11) of this subsection.”.
(c) Section 7 (D.C. Official Code § 7-1671.06) is amended as follows:
(1) Subsection (h) is amended by striking the phrase "cultivation centers who
receive a manufacturer’s license pursuant to subsection (d) of this section.” and inserting the
phrase "cultivation centers and retailers, and applicants who scored 150 points or more during
the ABC Board open application period that occurred between November 29, 2021 and March
28, 2022, who receive a cultivation center, manufacturer, or retailer’s license pursuant to
subsections (d), (w), (x) and (y) of this section.”.
(2) Subsection (k)(1) is amended to read as follows:
“(k)(1) The ABC Board shall be authorized to issue a one-year conditional license for a
cultivation center, retailer, internet retailer, manufacturer, courier, or testing laboratory that does
not currently have a proposed location; except, that the ABC Board shall be authorized to
2
 ENROLLED ORIGINAL
convert a one-year conditional license to 2 years for a cultivation center or manufacturer that
does not currently have a proposed location.”.
(3) Subsection (n)(2) is amended to read as follows:
“(2)(A) The ABC Board shall, by rules issued pursuant to section 14, establish the
initial application and renewal fees for cultivation center, manufacturer, retailer, internet retailer,
and courier licenses. The ABC Board may revise these fees as considered necessary.
“(B) There shall be no initial application fee for a testing laboratory
license. Renewal fees for a testing laboratory license shall be established by rules issued pursuant
to sub-paragraph (A) of this paragraph.”.
(4) A new subsection (y) is added to read as follows:
“(y) The 5 cultivation center registration applicants that submitted medical
cannabis facility registration applications to the ABC Board between November 29, 2021 and
March 28, 2022, that scored 150 points or more shall automatically receive a manufacturer
license provided that the annual fee is paid after the effective date of the Medical Cannabis
Manufacturer Clarification Emergency Amendment Act of 2023, effective June 29, 2023 (D.C.
Act 25-152; 70 DCR 9410); provided, that the applicant registers on a form provided by ABCA
with the ABC Board by May 1, 2024.”.
Sec. 3. Fiscal impact statement.
The Council adopts the fiscal impact statement of the Budget Director as the fiscal impact
statement required by section 4a of the General Legislative Procedures Act of 1975, approved
October 16, 2006 (120 Stat. 2038; D.C. Official Code § 1-301.47a).
Sec. 4. Effective date.
This act shall take effect following approval by the Mayor (or in the event of veto by the
Mayor, action by the Council to override the veto), and shall remain in effect for no longer than
90 days, as provided for emergency acts of the Council of the District of Columbia in section
3
 ENROLLED ORIGINAL
412(a) of the District of Columbia Home Rule Act, approved December 24, 1973 (87 Stat. 788;
D.C. Official Code § 1-204.12(a)).
_____________________________________
Chairman
Council of the District of Columbia
_________________________________
Mayor
District of Columbia
4